173 related articles for article (PubMed ID: 36593171)
21. Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; El Sahly HM; George S; Winokur P; Edwards K; Brady RC; Rouphael N; Keitel WA; Mulligan MJ; Burton RL; Nakamura A; Ferreria J; Nahm MH
Vaccine; 2018 Jan; 36(5):606-614. PubMed ID: 29279281
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature.
Cripps AW; Folaranmi T; Johnson KD; Musey L; Niederman MS; Buchwald UK
Expert Rev Vaccines; 2021 Mar; 20(3):257-267. PubMed ID: 33567914
[No Abstract] [Full Text] [Related]
23. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
[TBL] [Abstract][Full Text] [Related]
24. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
Essink B; Sabharwal C; Cannon K; Frenck R; Lal H; Xu X; Sundaraiyer V; Peng Y; Moyer L; Pride MW; Scully IL; Jansen KU; Gruber WC; Scott DA; Watson W
Clin Infect Dis; 2022 Aug; 75(3):390-398. PubMed ID: 34940806
[TBL] [Abstract][Full Text] [Related]
25. Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years.
Chichili GR; Smulders R; Santos V; Cywin B; Kovanda L; Van Sant C; Malinoski F; Sebastian S; Siber G; Malley R
Vaccine; 2022 Jul; 40(31):4190-4198. PubMed ID: 35690500
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial.
Okinaka K; Akeda Y; Inamoto Y; Fuji S; Ito A; Tanaka T; Kurosawa S; Kim SW; Tanosaki R; Yamashita T; Ohwada C; Kurata K; Mori T; Onozawa M; Takano K; Yokoyama H; Koh K; Nagafuji K; Nakayama K; Sakura T; Takahashi T; Oishi K; Fukuda T
Clin Microbiol Infect; 2023 Apr; 29(4):482-489. PubMed ID: 36503114
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
Nakashima K; Aoshima M; Ohfuji S; Yamawaki S; Nemoto M; Hasegawa S; Noma S; Misawa M; Hosokawa N; Yaegashi M; Otsuka Y
Hum Vaccin Immunother; 2018; 14(8):1923-1930. PubMed ID: 29561248
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
Mohapi L; Pinedo Y; Osiyemi O; Supparatpinyo K; Ratanasuwan W; Molina JM; Dagan R; Tamms G; Sterling T; Zhang Y; Pedley A; Hartzel J; Kan Y; Hurtado K; Musey L; Simon JK; Buchwald UK;
AIDS; 2022 Mar; 36(3):373-382. PubMed ID: 34750291
[TBL] [Abstract][Full Text] [Related]
29. Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.
Hammitt LL; Quinn D; Janczewska E; Pasquel FJ; Tytus R; Reddy KR; Abarca K; Khaertynova IM; Dagan R; Dawson R; McCauley J; Shekar T; Fu W; Pedley A; Sterling T; Tamms G; Musey L; Buchwald UK
Hum Vaccin Immunother; 2023 Dec; 19(1):2177066. PubMed ID: 36864601
[TBL] [Abstract][Full Text] [Related]
30. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
Thompson AR; Klein NP; Downey HJ; Patterson S; Sundaraiyer V; Watson W; Clarke K; Jansen KU; Sebastian S; Gruber WC; Scott DA; Schmöele-Thoma B
Hum Vaccin Immunother; 2019; 15(2):444-451. PubMed ID: 30303436
[TBL] [Abstract][Full Text] [Related]
31. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
[TBL] [Abstract][Full Text] [Related]
32. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study.
Haranaka M; Yono M; Kishino H; Igarashi R; Oshima N; Sawata M; Platt HL
Hum Vaccin Immunother; 2023 Aug; 19(2):2228162. PubMed ID: 37389808
[TBL] [Abstract][Full Text] [Related]
33. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
[TBL] [Abstract][Full Text] [Related]
34. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK
Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861
[TBL] [Abstract][Full Text] [Related]
35. Immunological Efficacy of Pneumococcal Vaccination Including the 13-Valent Pneumococcal Conjugate Vaccine in Adult Patients With Sickle Cell Disease: Results of the Randomized DREVAC Controlled Trial.
Melica G; Bartolucci P; Audureau E; Le Corvoisier P; Habibi A; Gellen J; Selmane D; Michel M; Lacabaratz C; Levy Y
Clin Infect Dis; 2023 Jun; 76(11):1949-1958. PubMed ID: 36705266
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
Stacey HL; Rosen J; Peterson JT; Williams-Diaz A; Gakhar V; Sterling TM; Acosta CJ; Nolan KM; Li J; Pedley A; Benner P; Abeygunawardana C; Kosinski M; Smith WJ; Pujar H; Musey LK
Hum Vaccin Immunother; 2019; 15(3):530-539. PubMed ID: 30648919
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults.
Shiramoto M; Hanada R; Juergens C; Shoji Y; Yoshida M; Ballan B; Cooper D; Gruber WC; Scott DA; Schmoele-Thoma B
Hum Vaccin Immunother; 2015; 11(9):2198-206. PubMed ID: 26176163
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
Esposito S; Tansey S; Thompson A; Razmpour A; Liang J; Jones TR; Ferrera G; Maida A; Bona G; Sabatini C; Pugni L; Emini EA; Gruber WC; Scott DA; Principi N
Clin Vaccine Immunol; 2010 Jun; 17(6):1017-26. PubMed ID: 20427630
[TBL] [Abstract][Full Text] [Related]
40. Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial.
Borys D; Rupp R; Smulders R; Chichili GR; Kovanda LL; Santos V; Malinoski F; Siber G; Malley R; Sebastian S
Vaccine; 2024 Apr; 42(10):2560-2571. PubMed ID: 38360475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
